皮肤科免疫抑制患者的 COVID 疫苗推荐：大流行期间的经验教训。
COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.
机构信息
Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.
出版信息
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
BACKGROUND
Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents.
AIM AND METHOD
Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology.
RESULT
In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting.
CONCLUSION
Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity.
背景
由于紧急情况，SARS-CoV2 疫苗在缺乏足够长期监测的情况下获得批准，因此对于接受不同免疫抑制剂治疗的患者，关于接种疫苗的时间和方案出现了一些问题。
目的与方法
在这里，我们介绍了皮肤科领域中此类患者的 SARS-CoV-2 疫苗接种的不同方面。
结果
简而言之，建议所有皮肤科患者接种 SARS-CoV-2 疫苗，无论其疾病和治疗方案如何。然而，由于这种情况下疫苗的免疫原性降低，应特别考虑免疫抑制治疗及其与疫苗接种时间的关系。
结论
新型生物免疫疗法不仅在安全性和选择性功能方面优于传统的全身治疗，而且在这方面，它们中的许多疗法不会影响疫苗的免疫原性。
Zotero 插件